Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.79 |
| ▸ | HPGD | P15428 | 2/20 | 0.79 |
| ▸ | HTT | P42858 | 2/20 | 0.79 |
| ▸ | MEN1 | O00255 | 2/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.79 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.79 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.53 |
| ▸ | NCOA1 | Q15788 | 2/20 | 0.52 |
| ▸ | NCOA3 | Q9Y6Q9 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.49 |
| ▸ | TUBB | P07437 | 1/20 | 0.49 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.49 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.49 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL797563 | 0.89 | KDM4E (1.00) | KDM4EHPGDHTTMEN1KMT2A | |
| SCHEMBL6882020 | 0.80 | KDM4E (0.81) | KDM4EHPGDHTTMEN1KMT2A | |
| SCHEMBL14259277 | 0.73 | PRKD1 (0.66) | KDM4EHPGDHTTMEN1KMT2A | |
| SCHEMBL5263677 | 0.73 | MAPT (0.69) | KDM4EHPGDHTTMEN1KMT2A | |
| SCHEMBL6350624 | 0.73 | KDM4E (0.69) | KDM4EHPGDHTTMEN1KMT2A | |
| SCHEMBL6237719 | 0.73 | KDM4E (0.69) | KDM4EHPGDHTTMEN1KMT2A | |
| SCHEMBL1655185 | 0.73 | PRKD1 (0.84) | KDM4EHPGDHTTMEN1KMT2A | |
| SCHEMBL6241086 | 0.73 | KDM4E (1.00) | KDM4EHPGDHTTMEN1KMT2A | |
| SCHEMBL940853 | 0.73 | KDM4E (0.65) | KDM4EHPGDHTTMEN1KMT2A | |
| SCHEMBL2882593 | 0.73 | KDM4E (0.65) | KDM4EHPGDHTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140194429-A1 | COMPOSITIONS FOR TREATMENT OF CANCER | NOVARX CORPORATION | 2014-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194429-A1 | COMPOSITIONS FOR TREATMENT OF CANCER | TP53, MCL1, CD44 | KDM4E 3891/4885HPGD 917/4885HTT 3197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.